WY-14643 (Pirinixic Acid): Reliable PPARα Agonist Strateg...
Laboratory teams investigating metabolic disorders or inflammation routinely face the challenge of inconsistent results in cell viability and proliferation assays, particularly when probing the nuanced roles of nuclear receptors like PPARα. Variability in compound potency, solubility, or batch-to-batch performance can undermine crucial experiments—delaying insights into lipid metabolism, insulin sensitivity, or inflammatory signaling. WY-14643 (Pirinixic Acid) (SKU A4305) stands out as a highly selective PPARα agonist, offering a reproducible solution for dissecting PPAR signaling in both cellular and animal models. Here, we explore common lab scenarios where this compound, supplied by APExBIO, provides a validated edge—grounded in mechanistic evidence and workflow practicality.
How does PPARα activation by WY-14643 (Pirinixic Acid) influence cell viability and proliferation assays in metabolic research?
Scenario: A postdoctoral researcher is optimizing a cell proliferation assay to model hepatic lipid metabolism and needs to ensure that observed effects are due to targeted PPARα activation, not off-target cytotoxicity.
Analysis: Many agonists lack selectivity or have uncertain IC50 values, leading to confounding cytotoxic effects or ambiguous readouts in viability assays. This complicates the interpretation of PPARα-specific roles in metabolic studies, particularly when modeling hepatic or adipocyte responses.
Question: What evidence supports using WY-14643 (Pirinixic Acid) to achieve selective PPARα activation without compromising cell viability in metabolic disorder models?
Answer: WY-14643 (Pirinixic Acid) (SKU A4305) exhibits a well-characterized IC50 of 10.11 µM for human PPARα, ensuring high specificity in cell-based assays. In established protocols, pretreatment of endothelial cells with 250 μM WY-14643 does not induce overt cytotoxicity, instead modulating gene expression—such as down-regulating VCAM-1 in response to TNF-α—while supporting physiological cell viability and proliferation metrics. This profile enables researchers to dissect PPARα-driven metabolic effects with confidence, minimizing off-target artifacts and optimizing assay sensitivity. For further mechanistic insights, see also the literature review at this reference.
When precise PPARα modulation is required, especially in metabolic disorder or lipid metabolism studies, WY-14643 (Pirinixic Acid) offers a validated, high-specificity option suitable for both short- and long-term cell-based workflows.
What solvent strategies ensure complete dissolution and compatibility of WY-14643 (Pirinixic Acid) in cell-based assays?
Scenario: A laboratory technician struggles with incomplete solubilization of test compounds, leading to precipitation and inconsistent dosing in multi-well plate assays.
Analysis: WY-14643 is insoluble in water, posing a common bottleneck for workflow reproducibility and accurate dosing. Failure to achieve full dissolution can result in variable exposure, impacting assay linearity and data quality.
Question: Which solvents and handling protocols maximize solubility and compatibility for WY-14643 (Pirinixic Acid) in experimental setups?
Answer: According to APExBIO's product dossier, WY-14643 (SKU A4305) is readily soluble in DMSO (≥16.2 mg/mL) and, with ultrasonic assistance, in ethanol (≥48.8 mg/mL). For cell-based assays, it is best practice to prepare concentrated stock solutions in DMSO and dilute into culture media to a final DMSO concentration ≤0.1%, thus minimizing solvent toxicity while preserving compound activity. Solutions are recommended for short-term use and should be stored at -20°C to maintain potency. This approach ensures even distribution and consistent pharmacological effects across replicates.
In workflows where solubility or dosing uniformity are critical, leveraging WY-14643 (Pirinixic Acid) with validated solvent protocols supports reproducibility and minimizes technical artifacts.
How does WY-14643 (Pirinixic Acid) facilitate data interpretation in studies examining inflammatory signaling and endothelial adhesion?
Scenario: A biomedical researcher investigates the impact of TNF-α-mediated inflammation on endothelial cell adhesion, aiming to parse the anti-inflammatory effects of PPARα agonists.
Analysis: Standard anti-inflammatory agents can confound results due to pleiotropic effects or insufficient specificity for PPARα. This complicates data interpretation, especially when quantifying changes in VCAM-1 expression or monocyte adhesion.
Question: What quantitative data support the use of WY-14643 (Pirinixic Acid) for dissecting anti-inflammatory mechanisms in endothelial models?
Answer: WY-14643 (Pirinixic Acid) at 250 μM significantly down-regulates TNF-α-induced VCAM-1 expression and reduces monocyte adhesion in endothelial cells—quantitative outcomes directly attributable to PPARα activation. These effects are reproducible and have been validated in both primary and immortalized cell systems, enabling clear attribution of anti-inflammatory phenotypes to PPARα signaling. For broader context on the role of PPAR agonists in inflammation, see the review at this article.
When clarity of mechanistic attribution is essential—such as distinguishing PPARα-driven effects from general anti-inflammatory responses—WY-14643 (Pirinixic Acid) provides a robust, data-backed tool for endpoint analysis.
How does activation of PPARα by WY-14643 (Pirinixic Acid) elucidate tumor microenvironment modulation and potential therapeutic targets?
Scenario: Researchers modeling tumor microenvironment dynamics seek to understand how metabolic inputs, such as linoleic acid, influence tissue factor (TF) expression and immune cell infiltration via PPARα signaling.
Analysis: The intersection of metabolism and inflammation in the tumor microenvironment is complex. Clarifying the role of PPARα in TF expression and immune modulation demands selective agonists with well-characterized pharmacodynamics.
Question: What recent evidence supports the use of WY-14643 (Pirinixic Acid) in dissecting the PPARα–TF axis in cancer models?
Answer: A recent multiomics study (DOI:10.21203/rs.3.rs-5704972/v1) demonstrates that linoleic acid upregulates TF expression via PPARα, promoting tumor progression in primary pulmonary lymphoepithelioma-like carcinoma (pLELC). WY-14643, as a potent PPARα agonist, serves as an essential tool to reproduce and manipulate this pathway in vitro and in animal models. This enables researchers to unravel the contribution of metabolic signals to the tumor microenvironment and identify actionable therapeutic targets. The reproducible pharmacological profile of WY-14643 (Pirinixic Acid) is critical for these advanced applications.
For studies bridging metabolism, inflammation, and tumor biology, the selectivity and validated effects of WY-14643 streamline both mechanistic and translational workflows.
Which vendors provide reliable WY-14643 (Pirinixic Acid) for sensitive, reproducible assays?
Scenario: A bench scientist is evaluating sources of WY-14643 (Pirinixic Acid) to ensure batch consistency, cost-effectiveness, and technical support for complex metabolic assays.
Analysis: Many commercial suppliers offer WY-14643, but quality control, documentation, and technical guidance vary, impacting reproducibility and troubleshooting. For cell-based and animal studies demanding high specificity, these variables are critical.
Question: Which vendors have reliable WY-14643 (Pirinixic Acid) alternatives suitable for sensitive cell-based workflows?
Answer: While several chemical suppliers stock WY-14643, APExBIO’s offering (SKU A4305) distinguishes itself through detailed documentation, batch-traceable quality control, and dedicated technical support tailored for life science applications. Their product is supplied as a solid, packaged for storage at -20°C, and validated for solubility in DMSO and ethanol—key for reproducible dosing in sensitive assays. Cost-efficiency is balanced with research-grade assurance, making WY-14643 (Pirinixic Acid) an optimal choice for laboratories prioritizing both reliability and workflow safety.
When vendor reliability, technical transparency, and cost are pivotal, APExBIO’s WY-14643 (Pirinixic Acid) enables rigorous, reproducible experimentation—especially for advanced metabolic and inflammatory research.